Skip Navigation

Internal Medicine

Evaluation of Exenatide ER (Bydureon) on the duration of diabetic remisison in cats

TitleEvaluation of Exenatide ER (Bydureon) on the duration of diabetic remisison in cats
Contact Person Audrey Cook, Dip ACVIM (Internal Medicine); Dip ABVP (Feline Practice)
Hospital Phone: 979-845-2351
Email: akcook@cvm.tamu.edu
Species Cats
Inclusion Criteria and General Background Information

Cats with a recent history (4-12 weeks) of diabetic remission.

Remission is defined as a blood glucose <200 mg/dl for >2 weeks without insulin administration.

Exclusion Criteria Cats with severe concurrent disease(s) are not eligible for this trial.
Owner Commitments

Cats will be examined at the hospital once a month and given either Exenatide ER or placebo by subcutaneous injection. Trial duration is 12 months or the recurrence of diabetes mellitus (which ever is sooner).

Financial Incentives

There is no cost for participation in this trial.

Cats will receive a full evaluation at the time of enrollment, which will include blood and urine testing. Expenses associated with every examination and all diagnostic testing will be covered by the trial. There is no costs associated with administration of Exenatide or placebo.

There are no financial benefits for participation in this trial.

This trial is currently open!

Study Information

Phase II Rapamycin Clinical Trial

TitlePhase II Rapamycin Clinical Trial
Contact Person

Jaime Brannan
rapaphase2@dogagingproject.com

Species Dogs
Inclusion Criteria and General Background Information

50 dogs are required to complete the study
・Dogs must be healthy and cooperative for physical exam.
・Dogs must be 6-10 years old, and 40-80 pounds in size.
・Dogs must be heartworm test negative and receiving consistent heartworm prevention.
・Medical history, physical examination and blood and urine tests will be used to determine health status.

The study duration is one year, and all dogs will be enrolled in College Station, Texas. Enrolled dogs will be randomized to receive rapamycin or placebo for 6 months, and monitored for a year. Dogs will be examined 4 times over the course of the year and owners will complete health-related questionnaires at each study-related visit and periodically throughout the year.

Exclusion Criteria More than 50 dogs will be screened for enrollment and dogs will be excluded if:
・They are not cooperative for physical or cardiac exam.
・Evidence of systemic illness is found on history, physical examination or blood and urine tests.
Owner Commitments

Owners must be able to:
・Attend 4 scheduled veterinary visits in College Station over the period of one year.
・Administer study medication (rapamycin or placebo) as directed for 6 months.
・Complete periodic surveys and questionnaires about their dogs, as well as keep a diary of drug administration.

Financial Incentives

The costs of all four veterinary visits, including cardiac examinations, diagnostic testing, and study drug, will be covered by the study.

Study Information